• Active, not recruiting

NCT02561962: A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma

Updated: Jun 13

NCT02561962: A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma


amg224

A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma


This is a first in human phase 1 multicenter open label study in subjects with relapsed or refractory multiple myeloma.


Sponsor

Amgen


Multiple Locations

International Study

 

ClinicalTrials.gov Identifier: NCT02561962


Official Title: A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 224 in Subjects With Relapsed or Refractory Multiple Myeloma

First Posted: September 28, 2015


Click here for details on ClinicalTrials.gov

 

Drug: AMG 224


AMG 224


Anti-BCMA Antibody-drug Conjugate AMG 224 (Code C162528)

AMG 224

AMG-224

AMG224

Anti-BCMA Antibody-drug Conjugate AMG 224

 

Leukemia;2021

Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma

Click here for details

 

Locations

United States, California

United States, Massachusetts

United States, New York

United States, Texas

Australia, Victoria


Posts Archive